Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NRXS Stock Forecast 2026-2027
$6.75
Current Price
$83.97M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to NRXS Price Targets
+92.6%
To High Target of $13.00
+63.0%
To Median Target of $11.00
+33.3%
To Low Target of $9.00
NRXS Price Momentum
-5.5%
1 Week Change
-5.6%
1 Month Change
+157.6%
1 Year Change
+48.7%
Year-to-Date Change
-27.7%
From 52W High of $9.33
+207.4%
From 52W Low of $2.20
📊 TOP ANALYST CALLS
Did NRXS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Neuraxis is one of their latest high-conviction picks.
Latest NRXS Stock Price Targets & Analyst Predictions
Based on our analysis of 1 Wall Street analyst, NRXS has a bullish consensus with a median price target of $11.00 (ranging from $9.00 to $13.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $6.75, the median forecast implies a 63.0% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NRXS Analyst Ratings
2
Buy
0
Hold
0
Sell
NRXS Price Target Range
Low
$9.00
Average
$11.00
High
$13.00
Current: $6.75
Latest NRXS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NRXS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 20, 2026 | Craig-Hallum | Buy | Maintains | $N/A | |
| Dec 22, 2025 | Craig-Hallum | Buy | Maintains | $N/A | |
| Jun 16, 2025 | Craig-Hallum | Buy | Initiates | $N/A |
Neuraxis Inc. (NRXS) Competitors
The following stocks are similar to Neuraxis based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Neuraxis Inc. (NRXS) Financial Data
Neuraxis Inc. has a market capitalization of $83.97M with a P/E ratio of -7.1x. The company generates $4.28M in trailing twelve-month revenue with a -170.1% profit margin.
Revenue growth is +79.5% quarter-over-quarter, while maintaining an operating margin of -108.3% and return on equity of -242.5%.
Valuation Metrics
Market Cap
$83.97M
Enterprise Value
$78.48M
P/E Ratio
-7.1x
PEG Ratio
0.2x
Price/Sales
19.9x
Growth & Margins
Revenue Growth (YoY)
+79.5%
Gross Margin
+86.4%
Operating Margin
-108.3%
Net Margin
-170.1%
EPS Growth
+79.5%
Financial Health
Cash/Price Ratio
+8.5%
Current Ratio
2.9x
Debt/Equity
6.2x
ROE
-242.5%
ROA
-77.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Neuraxis Inc. (NRXS) Business Model
About Neuraxis Inc.
What They Do
Develops innovative medical solutions for neurological health.
Business Model
Neuraxis Inc. generates revenue through the development and commercialization of therapies targeting various neurological disorders. By leveraging advanced research and technology, the company aims to create breakthrough treatments that can be marketed to healthcare providers and pharmaceutical companies.
Additional Information
The company's focus on neurological health is increasingly relevant due to the rising global prevalence of neurological disorders. Neuraxis Inc. plays a significant role in the biotech sector, aiming to improve patient outcomes and quality of life while influencing market dynamics with its research-driven innovations.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
24
CEO
Mr. Brian Carrico
Country
United States
IPO Year
2023
Website
neuraxis.comNeuraxis Inc. (NRXS) Latest News & Analysis
Latest News
Quick Summary
NRXS reported strong first-quarter 2026 results, with rising revenue and expanding gross margin due to improved reimbursement under the Category I CPT code.
Why It Matters
NRXS' rising revenue and gross margin indicate strong market performance and improved reimbursement, suggesting potential for future profitability and growth, which can attract more investment.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
NeurAxis, Inc. (NRXS) has released its Q1 2026 earnings call transcript, providing insights into its financial performance and strategic direction.
Why It Matters
NeurAxis, Inc.'s Q1 2026 earnings call reveals financial performance and strategic updates, impacting stock valuation and investor sentiment regarding future growth potential.
Source: Seeking Alpha
Market Sentiment:
Neutral
NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth
2 months ago
Quick Summary
NeurAxis, Inc. (NYSE American: NRXS) reported its Q1 2026 results, focusing on neuromodulation therapies for chronic conditions in children and adults. Further details on performance were not provided.
Why It Matters
NeurAxis's Q1 results may signal growth or challenges in neuromodulation therapies, impacting investor confidence and stock performance in the medical tech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026
2 months ago
Quick Summary
NeurAxis, Inc. (NYSE American: NRXS) will report its Q1 2026 financial results on May 12, 2026, before market open, followed by a conference call at 9:00 am ET.
Why It Matters
NeurAxis's upcoming financial results and conference call could impact stock performance, reflecting the company's growth potential and investor confidence in its neuromodulation therapies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
NeurAxis, Inc. announced that four health insurers have added coverage for its IB-Stim treatment via PENFS, expanding access to 1.25 million lives in five states.
Why It Matters
NeurAxis's expansion of insurance coverage for its PENFS treatment enhances market access, potentially increasing revenue and patient adoption, making it a key development for investors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
NeurAxis, Inc. Announces Preferred Stock Dividend
3 months ago
Quick Summary
NeurAxis, Inc. (NYSE American: NRXS) announced a dividend declaration for its Series B Preferred Stock on April 10, 2026.
Why It Matters
NeurAxis's dividend declaration on Series B Preferred Stock signals financial stability and potential returns, which may boost investor confidence and interest in the stock.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About NRXS Stock
What is Neuraxis Inc.'s (NRXS) stock forecast for 2027?
Based on our analysis of 1 Wall Street analysts, Neuraxis Inc. (NRXS) has a median price target of $11.00. The highest price target is $13.00 and the lowest is $9.00.
Is NRXS stock a good investment in 2027?
According to current analyst ratings, NRXS has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.75. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NRXS stock?
Wall Street analysts predict NRXS stock could reach $11.00 in the next 12 months. This represents a 63.0% increase from the current price of $6.75. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Neuraxis Inc.'s business model?
Neuraxis Inc. generates revenue through the development and commercialization of therapies targeting various neurological disorders. By leveraging advanced research and technology, the company aims to create breakthrough treatments that can be marketed to healthcare providers and pharmaceutical companies.
What is the highest forecasted price for NRXS Neuraxis Inc.?
The highest price target for NRXS is $13.00 from at , which represents a 92.6% increase from the current price of $6.75.
What is the lowest forecasted price for NRXS Neuraxis Inc.?
The lowest price target for NRXS is $9.00 from at , which represents a 33.3% increase from the current price of $6.75.
What is the overall NRXS consensus from analysts for Neuraxis Inc.?
The overall analyst consensus for NRXS is bullish. Out of 1 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $11.00.
How accurate are NRXS stock price projections?
Stock price projections, including those for Neuraxis Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 18, 2026 2:44 AM UTC